- Home
- RNAZ vs HYZN Comparison
RNAZ vs HYZN Comparison
Compare RNAZ & HYZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- HYZN
- Stock Information
- Founded
- RNAZ 2016
- HYZN 2020
- Country
- RNAZ United States
- HYZN United States
- Employees
- RNAZ N/A
- HYZN N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- HYZN Construction/Ag Equipment/Trucks
- Sector
- RNAZ Health Care
- HYZN Consumer Discretionary
- Exchange
- RNAZ Nasdaq
- HYZN Nasdaq
- Market Cap
- RNAZ 8.3M
- HYZN 9.2M
- IPO Year
- RNAZ 2021
- HYZN N/A
- Fundamental
- Price
- RNAZ $0.32
- HYZN $1.32
- Analyst Decision
- RNAZ Strong Buy
- HYZN Strong Buy
- Analyst Count
- RNAZ 1
- HYZN 1
- Target Price
- RNAZ $3.00
- HYZN $80.00
- AVG Volume (30 Days)
- RNAZ 606.0K
- HYZN 2.3M
- Earning Date
- RNAZ 11-26-2024
- HYZN 11-13-2024
- Dividend Yield
- RNAZ N/A
- HYZN N/A
- EPS Growth
- RNAZ N/A
- HYZN N/A
- EPS
- RNAZ N/A
- HYZN N/A
- Revenue
- RNAZ N/A
- HYZN $10,725,000.00
- Revenue This Year
- RNAZ N/A
- HYZN $3,703.39
- Revenue Next Year
- RNAZ $100.00
- HYZN N/A
- P/E Ratio
- RNAZ N/A
- HYZN N/A
- Revenue Growth
- RNAZ N/A
- HYZN 1237.25
- 52 Week Low
- RNAZ $0.22
- HYZN $1.43
- 52 Week High
- RNAZ $18.68
- HYZN $63.00
- Technical
- Relative Strength Index (RSI)
- RNAZ 33.05
- HYZN 32.32
- Support Level
- RNAZ $0.31
- HYZN $1.58
- Resistance Level
- RNAZ $0.49
- HYZN $1.76
- Average True Range (ATR)
- RNAZ 0.05
- HYZN 0.13
- MACD
- RNAZ -0.02
- HYZN 0.01
- Stochastic Oscillator
- RNAZ 12.67
- HYZN 7.29
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About HYZN Hyzon Motors Inc.
Hyzon Motors Inc assembles and supplies hydrogen fuel cell-powered commercial vehicles across North America, Europe, China, and Australasia. In addition, it builds and fosters a clean hydrogen supply ecosystem with partners from feedstocks through production, dispensing and financing. The company intends to meet its customers' zero-emission vehicle needs by electrifying proven vehicle platforms utilizing its industry- leading fuel cell and electric propulsion technologies. It expects to deploy these technologies in various vehicle classes, including heavy-duty and medium-duty trucks and buses with the potential for future expansion into light-duty commercial vehicles, additional mobility use cases and stationary power applications.